December 8, 2025BloodOpen Access

Fludarabine and cytarabine is not superior to high dose cytarabine as consolidation therapy in standard risk AML in children: Results from the international Phase III MyeChild01 trial

View Full Paper

Ask AI

Bookmark

Authors

OSOwen SmithUniversity College Dublin GSGeoff ShentonNewcastle upon Tyne Hospitals NHS Foundation Trust CRC. RénardUniversité Claude Bernard Lyon 1

Discussion

Member takes

Implication

Randomised trial found high dose cytarabine improves outcomes over fludarabine in children with standard risk acute myeloid leukemia, highlighting treatment implications.

Key Points

High dose cytarabine led to better outcomes in standard risk acute myeloid leukemia compared to fludarabine.
Two-year relapse-free survival was 78% for high dose cytarabine and 70% for fludarabine.
Observational analysis included 360 patients randomized to receive fludarabine or high dose cytarabine.
Further exploration needed for risk stratified treatment implications in acute myeloid leukemia.

Cite This Study

Smith et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e19a https://doi.org/10.1182/blood-2025-879

View Full Paper

Ask AI

Bookmark

Implication

Randomised trial found high dose cytarabine improves outcomes over fludarabine in children with standard risk acute myeloid leukemia, highlighting treatment implications.

Fludarabine and cytarabine is not superior to high dose cytarabine as consolidation therapy in standard risk AML in children: Results from the international Phase III MyeChild01 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Fludarabine and cytarabine is not superior to high dose cytarabine as consolidation therapy in standard risk AML in children: Results from the international Phase III MyeChild01 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider